The TAILORx Breast Cancer Trial
The majority of women with early-stage breast cancer are advised to receive chemotherapy in addition to radiation and hormonal therapy, yet research has not demonstrated that chemotherapy benefits all of them equally. TAILORx seeks to incorporate a molecular profiling test (a technique that examines many genes simultaneously) into clinical decision making, and thus spare women unnecessary treatment if chemotherapy is not likely to be of substantial benefit. TAILORx is one of the first trials to examine a methodology for personalizing cancer treatment.
The study has randomized approximately 7,000 women at 900 sites in the United States and Canada. Women recently diagnosed with estrogen-receptor and/or progesterone-receptor positive, Her2/neu-negative breast cancer that had not yet spread to the lymph nodes were eligible for the study. (See a summary of the TAILORx protocol for more information.)
TAILORx is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and is coordinated by the Eastern Cooperative Oncology Group (ECOG). All of the NCI-sponsored clinical trials groups that perform breast cancer research studies have collaborated in the trial’s development and are participating in this study.
About the Trial
Targeted Cancer Therapies
A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.
Molecular Targets in Cancer Therapy
The past two decades of biomedical research have yielded an enormous amount of information about the molecular events that take place during the development of cancer.
Program for the Assessment of Clinical Cancer Tests (PACCT)
The PACCT has been developed to ensure that development of the next generation of laboratory tests is efficient and effective.